Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts ≥300 cells/μL and HIV-1 suppression?

Clinical Infectious Diseases

Volumn 56, Issue 9, 2013, Pages 1340-1343

  Gale, Howard B ^a,c   Gitterman, Steven R ^a   Hoffman, Heather J ^b   Gordin, Fred M ^a,b   Benator, Debra A ^a,b   Labriola, Ann M ^a,b   Kan, Virginia L ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

CD4; CD4 count; HIV load; HIV suppression; HIV 1 RNA

Indexed keywords

INTERFERON; STEROID;

ARTICLE; CD4 LYMPHOCYTE COUNT; CHEMOTHERAPY; CONCURRENT INFECTION; DISEASE SEVERITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PATIENT MONITORING; PRIORITY JOURNAL; RADIOTHERAPY; VIRUS LOAD; VIRUS PNEUMONIA;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG MONITORING; HIV INFECTIONS; HIV-1; HUMANS; VIRAL LOAD;

EID: 84875971238     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit004     Document Type: Article

References (12)

1. Egger M, May M, Chêne G, et al. ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-29. (Pubitemid 34786200)
2. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services 2012. Available at: http://www.aidsinfo. nih.gov/guidelines/. Accessed 13 September 2012.
3. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58(RR-4):1-207.
4. Leukocyte differential count: diagnostic information and inferences. Lymphocytic series. In: Wu A, ed. Tietz clinical guide to laboratory tests. Philadelphia: W. B. Saunders Company, 2006: 1194-5.
5. Feeney C, Bryzman S, Kong L, Brazil H, Deutsch R, Fritz LC. T-lymphocyte subsets in acute illness. Crit Care Med 1995; 23:1680-5.
6. Williams RL. Product-limit survival functions with correlated survival times. Lifetime Data Anal 1995; 1: 171-86.
7. Lee EW, Wei LJ, Amato DA. Cox-type regression analysis for large numbers of small groups of correlated failure time observations. In: Klein JP, Goel PK, ed. Survival analysis: state of the art. Dordrecht: Kluwer Academic Publishers, 1992: 237-47.
8. Raboud JM, Haley L, Montaner JS, Murphy C, Januszewska M, Schechter MT. Quantification of the variation due to laboratory and physiologic sources in CD4 lymphocyte counts of clinically stable HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:S67-73.
9. Malone JL, Simms TE, Gray GC, Wagner KF, Burge JR, Burke DS. Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J Acquir Immune Defic Syndr 1990; 3:144-51. (Pubitemid 20080777)
10. Trotta MP, Cozzi-Lepri A, Ammassari A, et al; ICONA Foundation Study. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures. Clin Infect Dis 2010; 51:456-64.
11. Maggiolo F, Leone S. CD4+ T lymphocyte recovery in individuals with type 1 human immunodeficiency virus infection. Clin Infect Dis 2010; 51:465-7.
12. The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count